PRF Technologies and Dotz Nano sign term sheet on energy platform
PRF would license and ultimately sell its GridFeed energy platform to Dotz for $1.0 million while taking an equity stake, allowing PRF to focus on its drug pipeline.
PRF Technologies Ltd. (Nasdaq: PRFX) announced on November 3, 2026 that it had signed a non-binding term sheet with Dotz Nano Limited (ASX: DTZ) for a strategic collaboration aimed at expanding Dotz's presence in the AI-driven energy optimization market.1
Under the proposed deal, Dotz would commercialize and ultimately acquire PRF's DeepSolar/GridFeed AI energy platform for US$1.0 million, launching it under an exclusive license, while PRF would take an equity position in Dotz through a US$250,000 participation in Dotz's recently announced A$2.0 million placement.1 Dotz would operate and commercialize GridFeed under the exclusive license from closing, with ownership of the platform and its intellectual property transferring to Dotz once US$650,000 of the purchase price has been paid.1 Completion is subject to due diligence, approval by both companies' boards, and execution of definitive agreements.1
Dotz is a climate-technology company listed on the Australian Securities Exchange with operations in Israel, commercializing technologies designed to reduce energy consumption, with its Dotz Energy business focused on AI-driven energy optimization and managed energy infrastructure.1 PRF had developed GridFeed since acquiring the DeepSolar business in March 2025.1 In September 2026, PRF had announced plans to establish GridFeed as a standalone subsidiary to pursue strategic transactions, and the Dotz agreement is the result of that process.1
On the healthcare side, PRF reported preliminary, unaudited cash of approximately US$11.0 million as of September 30, 2026.1 LayerBio, PRF's majority-owned subsidiary, expects to begin enrolling patients before year-end in its U.S. multi-center Phase 2 trial of OcuRing-K, a bio-erodible intraocular ring designed to deliver ketorolac during cataract surgery.1 PRF is also continuing to advance PRF-110, its extended-release, opioid-sparing post-surgical pain candidate.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.